Pure Global AI
NCT05855278Completed

The Role of PET/MRI in Predicting the Outcome of Definitive Chemoradiotherapy for Esophageal Cancer Patients

Investigating the Role of Integrated 18FDG-PET/MRI in Predicting the Treatment Outcome of Definitive Chemoradiotherapy for Patients With Esophageal Cancer
Chang Gung Memorial HospitalClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Esophageal Cancer
Drug/Device/Intervention
PET/MRI
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Chang Gung Memorial Hospital
Location
Taoyuan, Taiwan
Timeline & enrollment
Phase
N/A
Start date
Aug 13, 2019
End date
Jun 30, 2022
Enrollment
22 participants
Primary outcome

Overall survival

Summary

PET/MRI has the advantage to assess the metabolism, diffusion, and perfusion parameters of
 the tumor simultaneously and has been investigated in some cancers with promising results. In
 this study, we prospectively investigate the role of PET/MRI in evaluating the outcome of
 patients with esophageal cancer treated by definitive chemoradiotherapy.

ICD-10 classifications
Carcinoma in situ: OesophagusMalignant neoplasm of oesophagusMalignant neoplasm: Middle third of oesophagusMalignant neoplasm: Overlapping lesion of oesophagusMalignant neoplasm: Upper third of oesophagus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05855278
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05855278 through Pure Global AI's free database. This phase not specified trial is sponsored by Chang Gung Memorial Hospital and is currently Completed. The study focuses on Esophageal Cancer. Target enrollment is 22 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.